MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ITRM had -$2,029K decrease in cash & cash equivalents over the period. -$7,459K in free cash flow.

Cash Flow Overview

Change in Cash
-$2,029K
Free Cash flow
-$7,459K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-8,979 -11,400
Depreciation
6 13
Amortization of intangible asset
349 687
Share-based compensation expense
53 117
Interest on short-term investments
0 0
Amortization of debt discount and deferred financing costs
0 194
Interest on notes - non-cash-Exchangeable Senior Subordinated Notes Due Two Thousand Twenty Five
0 88
Financing transaction costs included in financing activities
0 -
Interest on notes - non-cash-Promissory Note
562 853
Adjustments to fair value of derivatives
-673 -1,134
Other
-880 -940
Accounts receivable
448 -
Prepaid expenses and other current assets
984 1,212
Inventory
201 948
Accounts payable
-612 938
Accrued expenses
1,343 1,299
Income taxes
-89 54
Other liabilities
0 -568
Net cash used in operating activities
-7,447 -7,811
Purchases of property and equipment
12 2
Purchases of short-term investments
0 0
Proceeds from sale of short-term investments
0 0
Net cash (used in) / provided by investing activities
-12 -2
Repayment of exchangeable notes
0 14,745
Proceeds from issuance of ordinary shares, net of transaction costs
5,432 11,477
Net cash provided by financing activities
5,432 -3,268
Effect of exchange rates on cash and cash equivalents
-2 -18
Net (decrease) / increase in cash, cash equivalents and restricted cash
-2,029 -11,099
Cash and cash equivalents at beginning of period
24,159 -
Cash and cash equivalents at end of period
11,031 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Iterum Therapeutics plc (ITRM)

Iterum Therapeutics plc (ITRM)